After joining Astellas Pharma (formerly Fujisawa Pharmaceutical), after working in a sales position (MR), became a product manager at the sales headquarters.Experience new launches and expanded indications of various products from the primary area to the specialty area (organ / bone marrow transplantation, autoimmune diseases, rare diseases, respiratory diseases, allergic diseases, etc.).After that, as a new product planning, he was involved in the evaluation of product marketability and business feasibility, and from 2014, he experienced the formulation of business plans and the design and operation of a dedicated organization as the director of the transplant immunology area. Joined SymBio Pharmaceuticals Limited, a pharmaceutical bio-venture in 2016.He was involved in the launch of the blood cancer business as a marketing head, and later became the general manager of the company's sales and marketing division.In addition to building an in-house sales (pharmaceutical manufacturer / distributor) system specializing in the blood field and building a digital system, he is engaged in licensing business and alliance management.
Participated in FRONTEO in 2019, planning and directing business strategy for medical device development and launch using the world's first language analysis AI. Build a new business model for drug discovery and drug repositioning that utilizes AI technology. Appointed executive officer in 2021. Aiming to become the global leader as a life science company that integrates AI and medical care.